Trajan Holdings delivered solid FY2025 results with revenue up 7.4% to $166.5 million and improved profitability despite transient costs and a biotech syringe loss. The company refinanced debt and set an optimistic FY2026 guidance range.
Trajan Group Holdings has reported record FY25 revenue of $166.5 million, beating guidance and setting a solid foundation for FY26 with continued organic growth and improved profitability.
Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for FY25, marking a significant turnaround with a return to profit after tax attributable to owners of $2.2 million. The company also reduced net debt and improved EBITDA by 26.2%, driven by organic growth and strategic acquisitions.
Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.